NOUVEAUX DERIVES NAPHTALENIQUES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
2-Fluoro-N-[3-hydroxy-2-(7-methoxy-naphthalen-1-yl)-propyl]-acetamide (I), its enantiomers and base addition salts, are new. 2-Fluoro-N-[3-hydroxy-2-(7-methoxy-naphthalen-1-yl)-propyl]-acetamide of formula (I), its enantiomers and base addition salts, are new. An independent claim is included for th...
Saved in:
Main Authors | , , , , , , , |
---|---|
Format | Patent |
Language | French |
Published |
01.02.2008
|
Edition | 7 |
Online Access | Get full text |
Cover
Loading…
Summary: | 2-Fluoro-N-[3-hydroxy-2-(7-methoxy-naphthalen-1-yl)-propyl]-acetamide (I), its enantiomers and base addition salts, are new. 2-Fluoro-N-[3-hydroxy-2-(7-methoxy-naphthalen-1-yl)-propyl]-acetamide of formula (I), its enantiomers and base addition salts, are new. An independent claim is included for the preparation of (I). [Image] ACTIVITY : Hypnotic; Tranquilizer; Antidepressant; Cardiovascular-Gen; Gastrointestinal-Gen; Neuroleptic; Anorectic; Anticonvulsant; Antidiabetic; Antiparkinsonian; Nootropic; Antimigraine; Neuroprotective; Cerebroprotective; Contraceptive; Endocrine-Gen; Immunomodulator; Cytostatic. MECHANISM OF ACTION : Melatonin receptor binder. The ability of (I) to bind with melatonin was tested. The results showed that 2-fluoro-N-[3-hydroxy-2-(7-methoxy-1-naphthyl)propyl]acetamide exhibited an inhibition constant value of 7.7 nM and 0.5 nM to bind with melatonin receptors MT 1and MT 2, respectively. |
---|---|
Bibliography: | Application Number: MA20070030016 |